Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1025399

N#Cc1c(Cl)cccc1N1CCC(CC(=O)O)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.60
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
FFAR4 Q5NUL3 12/20 0.47
FFAR1 O14842 2/20 0.44
DRD3 P35462 1/20 0.44
CHRM4 P08173 1/20 0.43
RORC P51449 1/20 0.42
DPP4 P27487 1/20 0.42
PREP P48147 1/20 0.42
DPP9 Q86TI2 1/20 0.42
DPP7 Q9UHL4 1/20 0.42
GRM2 Q14416 1/20 0.40
KHK P50053 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13622662 0.93 GAA (0.67) GAAKDM4EALDH1A1L3MBTL1FFAR4
Trifluoroacetic Acid SCHEMBL1024487 0.88 KDM4E (0.56) GAAKDM4EALDH1A1FFAR4FFAR1
Trifluoroacetic Acid SCHEMBL1026535 0.87 FFAR4 (0.52) GAAKDM4EFFAR4FFAR1KHK
Trifluoroacetic Acid SCHEMBL4359200 0.87 FFAR4 (0.47) GAAKDM4EFFAR4FFAR1RORC
Trifluoroacetic Acid SCHEMBL1022982 0.84 FFAR4 (0.48) GAAKDM4EALDH1A1FFAR4FFAR1
SCHEMBL1025401 0.84 GAA (0.56) GAAKDM4EALDH1A1L3MBTL1FFAR4
Trifluoroacetic Acid SCHEMBL1025132 0.84 FFAR4 (0.46) GAAFFAR4FFAR1DRD3KHK
SCHEMBL13622678 0.83 KHK (0.48) GAAKDM4EFFAR4FFAR1RORC
Trifluoroacetic Acid SCHEMBL1024810 0.83 FFAR4 (0.55) FFAR4FFAR1CHRM4
SCHEMBL13622686 0.82 KDM4E (0.62) GAAKDM4EALDH1A1FFAR4DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK GAA 2377/4885KDM4E 248/4885ALDH1A1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.